Nevertheless, programmed cell death protein 1 (PD-1)/ programmed death-ligand 1 (PD-L1) axis inhibitor monotherapy only benefits a minority (29.6%) of selected NSCLC patients in the long term [1]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.